SCL Science Inc. (KOSDAQ:246960)

Market Cap	105.48B
Revenue (ttm)	5.87B
Net Income (ttm)	-4.73B
Shares Out	8.48M
EPS (ttm)	-649.96
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,384
Average Volume	247,241
Open	12,000
Previous Close	11,830
Day's Range	11,780 - 12,000
52-Week Range	7,530 - 13,020
Beta	0.45
RSI	91.93
Earnings Date	Aug 12, 2025

About SCL Science

SCL Science Inc. produces medical hemostatic agents using biomimetic technology. Its products includes BiMM (Bio-inspired Medical Materials) that reacts immediately with blood; Endoseal which is used for the specialized indication of gastrointestinal bleeding; InnoSeal, a hemostatic agent that is used in various surgical fields such as cardiology, radiology, and neurosurgery; Jelly Seal, a hemostasis and sealing products; STOP, a non-bleeding intravascular injection; Film that prevents leakage at intestinal and vascular anastomosis sites; and I...

• Industry: Orthopedic, Prosthetic, and Surgical Appliances and Supplies
• Founded: 2010
• Employees: 62
• Stock Exchange: KOSDAQ
• Ticker Symbol: 246960

Financial Performance

In 2024, SCL Science's revenue was 4.74 billion, an increase of 258.30% compared to the previous year's 1.32 billion. Losses were -3.73 billion, -25.79% less than in 2023.